Analysis of risk factors of surgical site infections in breast cancer

Chinese Medical Journal

Volumn 123, Issue 5, 2010, Pages 559-562

  Gao, Yang Xu ^a   Xu, Ling ^a   Ye, Jing Ming ^a   Wang, Dong Min ^a   Zhao, Jian Xin ^a   Zhang, Lan Bo ^a   Duan, Xue Ning ^a   Liu, Yin Hua ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Adjuvant treatment; Breast cancer; Surgical site infection

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INDWELLING CATHETER; MULTIPLE CYCLE TREATMENT; OPERATION DURATION; POSTOPERATIVE INFECTION; RISK FACTOR; SURGICAL APPROACH;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURGICAL WOUND INFECTION;

EID: 77949368919     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.05.010     Document Type: Article

References (14)

1. Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, et al. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J 2008; 121: 1965-1968.
2. Zhou B, Yang DQ, Xie F. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J 2008; 121: 387-391.
3. Yuan Z, Qu X, Zhang ZT, Wang Y. Neoadjuvant chemotherapy in patients with stages II and III breast cancer. Chin Med J 2009; 122: 2993-2997.
4. Ministry of Health of the People's Republic of China. Statute of Nosocomial Infectious Management (for Trial Implementation), 2000.
5. Arias CA, Quintero G, Vanegas BE, Rico CL, Patino JF. Surveillance of surgical site infection: decade of experience at a Columbian Tertiary Care centre. World J Surg; 2003, 27: 529-533.
6. Malone DL, Genuit T, Tracy JK, Gannon C, Napolitano LM. Surgical site infection: reanalysis of risk factors. J Surg Res 2002; 103: 89-95.
7. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20: 250-278; quiz 279-280.
8. Snezana B. Treatment of a febrile neutropenic patient. Arch Oncol 2004; 12: 179-181.
9. Dale DC. Colony stimulating factors for the management of neutropaenia in cancer patients. Drugs 2002; 62 (Suppl 1): S1-S15.
10. Yang Y, Fang H. Clinical analysis of nosocomial infections in chemotherapeutic patients with malignant tumors. J Pract Oncol 2003; 18: 476-477.
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (Accessed August 9, 2006 at http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pd f).
12. Huang ZQ, Yang JM, Chen L, Ni X, Lou JW, Wang JM. Efficacy comparisons of granulocyte colony stimulating factor in different post chemotherapeutic periods of acute leukemia. J Modern Med 2003; 31: 402-403.
13. NCCN Clinical Practice Guidelines in Oncology Breast Cancer Guideline (The Chinese edition), 1st, 2007: 31. (Accessed at http://www.nccn-asia.org/ cn/Adaptation.aspx? CatorID=51&KoID=5&Opsition=2007).
14. Dai WJ, Zhang QL. Correct applications of aseptic techniques. Chin J Pract Surg (Chin) 2008; 28: 38-40.